牧原股份(002714.SZ)12月生豬銷售收入28.16億元 同比增長85.75%
格隆匯1月6日丨牧原股份(002714.SZ)公佈,2019年12月份,公司銷售生豬82.72萬頭,同比下降38.18%;銷售收入28.16億元,同比增長85.75%;2019年12月份,公司商品豬銷售均價30.52元/公斤,比2019年11月份上漲0.73%。
2019年12月份,商品豬價格整體呈現上升趨勢。
2019年,公司共銷售生豬1025.33萬頭,其中商品豬867.91萬頭,仔豬154.71萬頭,種豬2.71萬頭。
進入冬季後,北方地區施工進度受影響,部分豬舍交付延期。截至2019年12月底,公司能繁母豬存欄為128.32萬頭,後備母豬存欄約72萬頭。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.